INVESTOR FAQS

INTELLECTUAL PROPERTY & TECHNOLOGY

Title

Q: What is the status of your patent filings?

A: We have a patent-pending status for our Organic Lipid Matrix Delivery System. This covers the specific homogenized structure of DHA/EPA within a semi-solid food matrix that bypasses the first-pass hepatic effect via lymphatic uptake. We are also in the process of filing international PCT applications to protect our manufacturing protocols in the EU and Asia. 

 

Q: Is the Omega Biotrack™ app proprietary?

A: Yes. The software architecture, the "biological progress" visualization logic, and the HIPAA-compliant data-handling layer are 100% owned by Nutreine USA. The app utilizes third-party lab APIs (e.g., OmegaQuant) but Nutreine retains the IP for the user-facing interface and the longitudinal database structure.

REGULATORY & COMPLIANCE 

Title

Q: How does the HSA/FSA (TrueMed) approval actually work?

A: TrueMed acts as the compliance partner that integrates into our checkout. They facilitate a brief clinical survey that generates a Letter of Medical Necessity (LMN) for the user. Because our products are formulated to treat/prevent clinical Omega-3 deficiency (a precursor to chronic disease), the IRS recognizes them as a "Qualified Medical Expense" under Section 213(d).

 

Q: Is the 65% NICU reduction claim FDA-approved?

A: We do not claim our product "prevents" preterm birth in a clinical sense. We make Structure/Function claims about DHA supporting fetal development, and we cite the Cetin 2024 study in an educational context to show that achieving the 8% biological state is associated with reduced risk. This separation of "Product" and "Biomarker Science" is a standard and compliant industry practice.

SUPPLY CHAINS & MARGINS

Title

Q: Why start in France if U.S. production is cheaper?

A: Integrity. Our French partner has already successfully executed our Batch 4 pilot runs with perfect lipid stability. Using them for the first 100,000 units guarantees that our "Founder’s Scholarship" participants get a flawless experience. Once the clinical proof is gathered, we switch to our vetted Florida-based co-manufacturer for the $1.50 scale-up.

 

Q: How do you get from $1.50 to $1.00 COGS in 2027?

A: The $0.50 reduction is driven by three levers: 

1.Direct Sourcing: Moving from middleman distributors to direct-from-origin algal oil contracts. 

2.Volume Rebates: Reaching MOQs (Minimum Order Quantities) of 5,000,000+ bars annually. 

3.Tolling Optimization: Transitioning from full-turnkey manufacturing to a tolling model where Nutreine buys raw ingredients directly. 

PARTNERSHIP & BUSINESS MODEL

Title

Q: Who owns the data from the Private Label lines (e.g., The Murray Protocol)? 

A: Nutreine USA owns 100% of the data. This is a non-negotiable term of our partnership LOIs. We provide the infrastructure (App/Testing/Fulfillment) in exchange for the fixed fee and the legal right to the anonymized longitudinal biological data. 

 

Q: What is the basis for your 4% attrition projection? 

A: We benchmark against "Outcome-Based" platforms rather than CPG snack brands. Whoop (~3% churn) and Noom (64% 9-month retention) demonstrate that when a user is tracking a specific health metric, the cost of cancellation (losing your data and your status) is high. 

REVENUE & FINANCIALS

Title

Q: What is the Founders' royalty model?

A: In lieu of traditional executive salaries, the Founders receive a $0.10 per bar royalty. This aligns management perfectly with the investor: if we aren't moving product and satisfying customers, we don't get paid.

 

Q: How is the $750k Bridge utilized? 

A: 33% Inventory: First 100k "Integrity Units" in France. 

27% Marketing: Activation of the 25k-person waitlist and Viral Leaderboard. 

20% Technology: Completion of the BioTrack App MVP. 

20% Operations: G&A, DC Rent, and legal/IP protection. 

THE EXIT

Title

Q: How is the company positioned for a high-multiple acquisition? 

A: We have intentionally de-risked the path to M&A by onboarding Jennifer Gettens, a former 22-year Nestlé executive. Jennifer maintains high-level ties and deep institutional relationships within the Nestlé ecosystem and the broader global CPG landscape. Her presence ensures that Nutreine has immediate "insider" access to decision-makers for potential acquisition scenarios. 

 

Q: Who are the likely acquirers? 

A: 1.Strategic CPG: Nestlé Health Science, Unilever, or Mars Edge (seeking a data-driven health platform). Jennifer Gettens provides the direct conduit to these entities. 

2.Wearable Ecosystems: Oura or Whoop (moving from "Tracking" to "Intervention"). 

3.Retail Chains: CVS or iHerb (seeking to own the exclusive clinical standard for their Wellness Hubs). 

What can I expect as a return?

See what a $50k investment could grow into

How is my investment protected?

Learn more about SAFE - Simple Agreement for Future Equity

RESERVE YOUR OMG8+ TODAY

 INVEST IN THE FUTURE OF HEALTH.

Thanks for contacting us. We'll get back to you as soon as possible.